| Genius Group Receives ICC Arbitration Award, Wins Return of 7.4 Million Shares and $8.0 Million Cash Payment |
Globe Newswire |
04/20 |
08:00 |
| Astec Names Chad Hartley Group President – Infrastructure Solutions |
Globe Newswire |
04/20 |
08:00 |
| Standard Dental Labs Inc. Appoints Brendan Cummins to Board of Directors |
Globe Newswire |
04/20 |
08:00 |
| Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq |
Globe Newswire |
04/20 |
08:00 |
| Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY® |
Globe Newswire |
04/20 |
08:00 |
| Cole West Closes on 38 Homesites in Northern Utah for New Community |
Globe Newswire |
04/20 |
08:00 |
| Atsena Therapeutics Receives Data Monitoring Committee Recommendation to Proceed with Pivotal Part C Cohort of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis |
Globe Newswire |
04/20 |
08:00 |
| Cycurion CEO Kevin Kelly Discusses Operational Execution, Multi‑Year Contract Momentum, and 2026 Growth Priorities in Recent Interview |
Globe Newswire |
04/20 |
08:00 |
| Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV108, an Allosteric SARM1 inhibitor |
Globe Newswire |
04/20 |
08:00 |
| Nanox Announces Fourth Quarter of 2025 Financial Results and Provides Business Updates |
Globe Newswire |
04/20 |
08:00 |
| Precedence Research Launches Advanced Cell and Gene Therapy Intelligence Platform to Transform Complex CGT Data into Strategic Decisions |
Globe Newswire |
04/20 |
07:58 |
| Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile |
Globe Newswire |
04/20 |
07:50 |
| Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source |
Globe Newswire |
04/20 |
07:42 |
| Thermal Imaging Market to Cross $8.78 Billion by 2034 at CAGR of 7.2%: New Research by The Insight Partners |
Globe Newswire |
04/20 |
07:39 |
| NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference |
Globe Newswire |
04/20 |
07:37 |
| BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting |
Globe Newswire |
04/20 |
07:30 |
| Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region |
Globe Newswire |
04/20 |
07:30 |
| Weight Watchers Appoints Proven Healthcare Executive Heather Thiltgen to Board of Directors |
Globe Newswire |
04/20 |
07:30 |
| Claire’s Place Foundation’s Glow Ride Returns to Hermosa Beach for CF Awareness Month |
Globe Newswire |
04/20 |
07:18 |
| New Found Gold Announces $205M Finance Package |
Globe Newswire |
04/20 |
07:15 |
| Toobit Announces $150,000 Event Contracts Campaign with Daily Win Rewards |
Globe Newswire |
04/20 |
07:12 |
| Gilat to Report First Quarter 2026 Results on Wednesday, May 13th |
Globe Newswire |
04/20 |
07:02 |
| Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) |
Globe Newswire |
04/20 |
07:01 |
| Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit |
Globe Newswire |
04/20 |
07:01 |
| Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates |
Globe Newswire |
04/20 |
07:00 |
